Weyco Group reported a 7% increase in net sales to $62.2 million for Q2 2026, driven by strong growth in its Florsheim brand and e-commerce sales. Net earnings surged to $13.3 million from $2.3 million in the prior year quarter, largely due to $15.3 million in tariff refunds following the invalidation of certain U.S. tariffs. The company also declared a $0.28 per share dividend and expects continued momentum into the second half of 2026 despite ongoing tariff uncertainties. Weyco's wholesale and retail segments both showed improved profitability, with tariff refunds significantly boosting margins.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
